An all-oral drug pair slowed advanced breast cancer, mostly in one mutation group
In the industry-funded evERA trial, giredestrant plus everolimus delayed progression of ER-positive breast cancer — but the clearest benefit was in ESR1-mutated tumours, and the endpoint was a surrogate, not survival.
| Group | Value (months) |
|---|---|
| Giredestrant + everolimus | 8.8 |
| Standard therapy + everolimus | 5.5 |
Most breast cancers are fuelled by the hormone oestrogen, and the mainstay of treatment is to choke off that signal. When the standard combination — a hormone-blocking drug plus a CDK4/6 inhibitor — stops working, options narrow. The evERA trial tested a new all-oral pairing for that setting: giredestrant, a next-generation oestrogen-receptor degrader, combined with everolimus, which blocks a separate growth pathway (mTOR) that tumours lean on when endocrine therapy fails [s1]. The combination delayed cancer progression — but the result comes with several qualifiers worth stating plainly. Giredestrant belongs to a class of oral drugs designed to replace fulvestrant, an older degrader that must be injected; everolimus is already used in this setting, so the trial was in effect testing whether swapping the hormonal partner improves on standard practice.
What the trial did
evERA was a phase 3, open-label, randomised trial funded by Genentech, which is developing giredestrant [s1][s2]. It enrolled patients with oestrogen-receptor-positive, HER2-negative locally advanced or metastatic breast cancer whose disease had progressed after a CDK4/6 inhibitor plus endocrine therapy [s1]. In all, 373 patients were randomly assigned 1:1 to either giredestrant plus everolimus or standard endocrine therapy — exemestane, fulvestrant, or tamoxifen — plus everolimus; 183 received the new combination and 190 the standard one [s1]. The primary endpoint was progression-free survival as judged by the treating investigators, tested first in patients whose tumours carried an ESR1 mutation and then across the whole trial [s1].
What it found
Among the 207 patients with ESR1-mutated tumours — a change that commonly drives resistance to standard hormone therapy — median progression-free survival was 10.0 months with giredestrant plus everolimus versus 5.5 months with standard therapy plus everolimus, a hazard ratio of 0.38 (95% confidence interval 0.27 to 0.54, P<0.001) [s1]. In the overall population, the figures were 8.8 versus 5.5 months, a hazard ratio of 0.56 (95% CI 0.44 to 0.71, P<0.001) [s1]. Side effects were common and broadly similar between groups, occurring in 98.9% of giredestrant-everolimus recipients and 96.8% of the comparison group; the most frequent were stomatitis (47.3% versus 48.9%), diarrhoea (26.9% versus 22.6%), and anaemia (23.6% versus 21.0%) [s1]. Much of that toxicity burden is attributable to everolimus, which both groups received; the near-identical side-effect profile suggests giredestrant did not add substantially to the harms of the backbone therapy [s1].
How to read it
The headline numbers are genuinely favourable, but three features determine how much weight to give them. First, the benefit is concentrated in ESR1-mutated tumours, where the hazard ratio of 0.38 is large; the overall-population effect is real but more modest, and much of it is carried by that mutation subgroup [s1]. This is a precision-oncology result — a reason to test for the mutation, not a blanket endorsement for every patient in this setting. ESR1 mutations typically emerge under the pressure of prior hormone therapy and are a recognised route by which tumours escape it, so a drug that works especially well against them fills a specific and growing gap.
Second, the endpoint is progression-free survival, a surrogate that measures how long scans stay stable, not how long people live. The trial did not report an overall-survival benefit at this analysis [s1]. Delaying progression matters to patients, but drugs that move a surrogate do not always extend life, and that distinction is routinely blurred in the way such results are promoted.
Third, the trial was open-label: both patients and the investigators judging progression knew who was getting the new drug [s1]. Because the primary endpoint rested on investigator assessment rather than a blinded independent review, there is room for expectation to colour the timing of a "progression" call — a known vulnerability of unblinded oncology trials. None of this erases the effect, especially the striking ESR1 result, but it argues for reading the overall-population figure as encouraging rather than definitive, and for waiting on survival data. The size of the ESR1 effect helps here: a hazard ratio of 0.38 is large enough that unblinding is unlikely to explain it away, whereas the more modest overall-population figure leaves more room for that kind of bias to matter.
Related coverage has examined what progression-free survival does and does not tell patients and an earlier trial where added therapy failed to improve survival.
What to watch
The practical questions now are whether the progression benefit eventually shows up as longer survival, and how giredestrant compares with the other oestrogen-receptor degraders competing for the same post-CDK4/6 niche [s1]. Mature overall-survival data from evERA will be the test that matters most.
This article describes research and is not medical advice. Cancer treatment decisions are a matter for patients and their oncology teams.
Sources
- Giredestrant plus Everolimus in Advanced Breast Cancer — New England Journal of Medicine, 1 October 2026
- evERA Breast Cancer trial registration (NCT05306340) — ClinicalTrials.gov
Sources
- Giredestrant plus Everolimus in Advanced Breast Cancer — New England Journal of Medicine , October 1, 2026
- A Phase III Study Evaluating Giredestrant Plus Everolimus Compared With Physician's Choice of Endocrine Therapy Plus Everolimus (evERA Breast Cancer, NCT05306340) — ClinicalTrials.gov, U.S. National Library of Medicine , October 1, 2026
More on
Atezolizumab added nothing to HER2-positive breast cancer therapy in IMpassion050
Final results of the phase 3 IMpassion050 trial show adding the immunotherapy atezolizumab to standard HER2-targeted treatment did not improve event-free or disease-free survival.
FDA clears vepdegestrant, a first-in-class PROTAC, for ESR1-mutated breast cancer
In VERITAC-2 the oral degrader more than doubled progression-free survival over fulvestrant in patients with an ESR1 mutation — 5.0 months versus 2.1 — but not in the trial as a whole.
FDA logs an imlunestrant efficacy approval for ER-positive advanced breast cancer
Eli Lilly's oral Inluriyo gained an FDA efficacy supplement on 18 September. In the phase 3 EMBER-3 trial, adding abemaciclib lifted median progression-free survival to 9.4 months from 5.5.
Drug conjugate plus immunotherapy delays advanced triple-negative breast cancer
In the phase 3 ASCENT-04 trial, sacituzumab govitecan with pembrolizumab lifted median progression-free survival to 11.2 months from 7.8 in PD-L1-positive disease. Survival data are immature.